Healthcare

According to a market report by Lucintel, the future of the pharmaceutical contract manufacturing market looks promising with opportunities in the big pharmaceutical, small & medium-sized pharmaceutical, and generic pharmaceutical markets. The global pharmaceutical contract manufacturing market is expected to reach an estimated $222.0 billion by 2028 with a CAGR of 7.3% from 2023 to 2028. The major drivers for this market are growing demand for generic and specialty medicines, increasing investments in pharmaceutical R&D activities, and rising trend for CMOs (contract manufacturing organization) for "one-stop-shop" benefit.



In this market manufacturing [API, FDF (parenteral, injectable, tablet, capsule, and oral liquid)], drug development, and biologics manufacturing are different segments of pharmaceutical contract manufacturing by services. Lucintel forecasts that biologics manufacturing will remain the largest segment over the forecast period due to increasing need for developing vaccines and biosimilars.  



Within this market, big pharmaceutical segment is expected to remain the largest segment due to growing trend among large pharmacies to contract out pharmaceutical production in order to minimise the pricing pressure and pipeline issues in their operations along with increasing demand for optimization of execution costs as bestselling medication patents expires.



APAC is expected to remain the largest region due to increasing demand from geriatric population, growing outsourcing activities and expansion of manufacturing capabilities of the local key players in the region.

Thermo Fisher Scientific, Catalent, Lonza, Almac Group, Recipharm, Patheon, Grifols International, Dalton Pharma Services, and AbbVie are the major suppliers in the global pharmaceutical contract manufacturing market.



Lucintel, a leading global strategic consulting and market research firm, has analysed growth opportunities in the global pharmaceutical contract manufacturing market by services, end use industry, and region. Lucintel has compiled a comprehensive research report titled “Growth Opportunities in the Global Pharmaceutical Contract Manufacturing Market 2023-2028: Trends, Forecast, and Opportunity Analysis.” The Lucintel report serves as a catalyst for growth strategy, as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes a forecast for the global pharmaceutical contract manufacturing market by services, end use industry, and region, as follows:

This more than 150-page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or email us at helpdesk@lucintel.com.

 

Lucintel, the premier global Management Consulting and market research firm, creates winning strategies for growth. Lucintel offers market assessments, competitive analysis, opportunity analysis, Growth Consulting, M&A, and Due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.

 

Q.1. What are some of the most promising, high-growth opportunities for the pharmaceutical contract manufacturing market by services (manufacturing [API, FDF (parenteral, injectable, tablet, capsule, and oral liquid)], drug development, and biologics manufacturing), end use industry (big pharmaceutical, small & medium-sized pharmaceutical, and generic pharmaceutical), and region (North America, Europe, Asia Pacific, and the Rest of the World)?

Q.2. Which segments will grow at a faster pace and why?

Q.3. Which region will grow at a faster pace and why?

Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?

Q.5. What are the business risks and competitive threats in this market?

Q.6. What are the emerging trends in this market and the reasons behind them?

Q.7. What are some of the changing demands of customers in the market?

Q.8. What are the new developments in the market? Which companies are leading these developments?

Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?

Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?

Q.11. What M&A activity did occur in the last five years and how did they impact the industry?